Blue Jet Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare's board approved audited FY25 results showing revenue from operations of ₹10,299.85 million, up about 45% from ₹7,115.98 million in FY24, while profit after tax jumped roughly 86% to ₹3,052.03 million (vs ₹1,637.51 million). The board recommended a final dividend of ₹1.2 per share (60%) on a face value of ₹2, subject to shareholder approval. It also approved a proposal to raise up to ₹15,000 million through QIP, preferential issue, private placement or a combination, subject to approvals. The company acquired a 30,366 sq meter industrial plot at Dahej III, Gujarat from GIDC for about ₹11.12 crore for manufacturing expansion. Statutory auditor KKC & Associates LLP issued an unmodified opinion, though the results note an income tax demand of ₹1,933.86 million (including ₹646.44 million interest) for AY 2020-21 to 2023-24 currently under appeal.
Strong top-line and bottom-line growth along with a healthy dividend are positives for shareholders, but the proposed ₹15,000 million capital raise may lead to equity dilution depending on the instrument mix. The pending income tax demand of nearly ₹1,934 million remains a material overhang, though the company believes it has a strong case on appeal.